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LETrERS TO THE EDITOR
The sex ratios of offspring and sibs of patients with cancer
Sir - Hawkins et al. (1995) present data on the sexes of
offspring of survivors of childhood leukaemia and non-
Hodgkin lymphomas. They are reproduced here in Table I
together with other data on the sexes of offspring of cancer
patients. The impression is given that illness is associated
with variation in the sex ratio (proportion male) of offspring
of patients. Two points are worth making:
(1) The association depends on the timing of the illness
vis-a-vis the conception of the offspring. In the data of
Olsson and Brandt (1982). the sex ratio of offspring of male
non-Hodgkin lymphoma patients is strongly associated with
the time of initiation of the disease (before or after age 50)
(X2 = 12.9. P<0.0005). So it seems that children sired before
the onset of the illness in men have a normal sex ratio.
whereas those sired after it contain a significant excess of
daughters.
(2) Inspection of the Table suggests that-at least in some
sets of data-male patients are more likely to produce female
offspnrng, and female patients male offspring. Such a
suggestion is reminiscent of data on the sex ratios of
offspnrng of patients with multiple sclerosis (MS). Before
disease onset, patients of both sexes produce children with
normal sex ratios. But after disease onset. male patients
produce a significant excess of daughters, and female patients
an excess of sons (James, 1994a).
Both points may be important in assessing the implications
of sex ratio disturbances in the offspring of cancer patients.
If (as in MS), the offspring sex ratio biases occur only
after disease onset, one may infer that these disturbances are
merely a (possibly hormonal) consequence of the disease (or
its treatment) and so probably throw no light on the cause of
the disease. In contrast, offspring sex ratio bias occurring
before disease onset suggests hormonal imbalance that is
causally associated with the disease. The point is illustrated
by the offspring sex ratio of patients who later develop
prostatic cancer. These men apparently sire an excess of sons
(James, 1990). This suggests that they already have high
androgen levels at the time of conception (James. 1987), i.e.
before disease onset. These high androgen levels are thought
to be causally associated with the disease.
In contrast. one might suspect that the excess of daughters
sired by men after contracting non-Hodgkin lymphoma is
merely a hormonal consequence of the disease. This
suggestion is supported by the low testosterone and high
LH levels reported by Olsson (1984) in men with non-
Hodgkin lymphoma.
Regardless of the timing of conceptions as regards disease
onset, a pattern in which men produce excess daughters may
be indicative of pathology. There are several male occupa-
tions in which low offspring sex ratios are thought to reflect
reproductive hazard e.g. divers. carbon setters and pesticide
sprayers (James. 1994b). Moreover men with one other
disease (besides MS and non-Hodgkin lymphoma). otosclero-
sis, reportedly sire an excess of daughters (James. 1989). All
of this may be explained simply by the observation that men
react to many (non-endocnrne) illnesses by diminished
secretion of testosterone and or increased gonadotrophins
(Semple, 1986).
I have noted that sex ratios of sibs (as well as of offspring)
of patients may throw light on possible hormonal imbalance
in the mother (James, 1991). In particular, sib sex ratios may
test those hypotheses suggesting that diseases are related to
hormone levels experienced by the patient when in utero.
namely cancers of the ovarian germ cell (Walker et al.. 1988)
and breast (Trichopoulos, 1990).
Meanwhile it should be emphasised that for offspring sex
ratios to be usefully exploited, the sexes of offspring must be
categorised simultaneously by (i) sex of parent and (ii)
whether the children were conceived before or after disease
onset.
William H James
The Galton Laboratory
University College London
Wolfson House
4 Stephenson Way
London NWl 2HE. UK
Table I The sexes of offspring of patients with cancer
AUale patients Female patients
M F M F Status ofparent
Hawkins et al. (1995) 78 79 130 95 SurVivors of childhood leukaemia and
non-Hodgkin lmphoma
Moe et al. (1979) 0 1 5 2 Survivors of acute lymphocytic leukaemia
Olsson and Brandt (1982) 21 49 15 24 Non-Hodgkin lymphoma onset age 30-49
84 63 64 55 Non-Hodgkin lymphoma onset age >50
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Tenascin and oncofetal fibronectin - oncofetal markers or indicators of
extraceliular matrix remodelling?
Sir - We read with interest the study on 'Immunohisto-
chemical expression of tenascin in normal stomach tissue,
gastnc carcinomas and gastric carcinoma in lymph nodes'
recently published in British Journal of Cancer (Ikeda et al.,
1995). In this study Ikeda et al. observed that tenascin, which
is not expressed in the adult mucosal and submucosal
connective tissue of the stomach, is expressed in the fibrous
stroma surrounding foci of cancer in 41% of primary
tumours and 32% of lymph node metastases (Ikeda et al.,
1995). They also observed that tenascin expression did not
correlate with any of the parameters evaluated in the study,
namely the degree of differentiation, abundance of fibrous
stroma, depth of invasion, lymph node metastasis and
prognosis.
We concur that their results show that 'tenascin appears
during the process of either malignant transformation or
tumour progression' (Ikeda et al., 1995). This does not mean,
however, that one can assume that tenascin expression is
stnctly associated to the neoplastic condition per se.
Moreover, we think Ikeda et al. have not obtained sufficient
evidence to substantiate the assumption that 'the positive
expression of tenascin may be useful as a stromal marker for
the early detection of gastric cancer' (Ikeda et al., 1995).
Firstly, they did not study precursor lesions of gastric
carcinoma, either as isolated lesions or as lesions in the
periphery of carcinomas, and thus missed the first steps of
gastnc carcinogenesis. Secondly, they did not include in their
study the analysis of non-cancerous conditions that may
induce the expression of tenascin (e.g. peptic ulcers with
granulation tissue and marked remodelling of the connective
tissue).
We raise these issues because we found that the
aforementioned conditions may cause false-positive results
when dealing with markers with oncofetal potential, such as
the so-called oncofetal fibronectin (onf-FN), an isoform of
fibronectin that some authors claim to be specifically
associated with malignant transformation (Matsuura and
Hakomori, 1989; London-Rosa et al., 1990; Mandel et al.,
1992). At variance with fibronectin, which is widely
distributed in normal tissues and particularly prominent in
the granulation tissue ofulcerated areas ofgastric carcinomas
(David et al., 1994), onf-FN was thought to appear
exclusively in the stroma of cancers, thus leading to the
possibility of using its detection in the diagnosis of the initial
steps of carcinogenesis (Loridon-Rosa et al., 1990; Mandel et
al., 1992). This is not the case because, apart from its
presence in gastric carcinoma, we observed strong immuno-
staining for onf-FN at the base of the three peptic ulcers
included in our study (David et al., 1993). Our findings thus
show that the production of onf-FN is not strictly associated
with malignancy, being dependent on a variety of conditions
having in common the capacity to induce deposition and/or
remodelling of extracellular matrix. We wonder whether this
is also the case for the expression of tenascin.
L David
M Sobrinho-Simoes
IPATIMUP
Medical Faculty of Porto
Hospital S. Joao
4200 Porto, Portugal
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